BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4620
- TODAY'S CHANGE (%)-0.0080 (-1.7021%)
- Bid / Lots0.4320/ 13
- Ask / Lots0.4620/ 1
- Open / Previous Close0.4800 / 0.4700
- Day Range
- 52 Week Range
- Volume338,151
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 7717 | 0.48 |
| 09:38 ET | 10791 | 0.4825 |
| 09:41 ET | 10830 | 0.48 |
| 09:48 ET | 6202 | 0.4988 |
| 09:50 ET | 6650 | 0.4986 |
| 09:52 ET | 3300 | 0.489189 |
| 09:56 ET | 5645 | 0.4802 |
| 09:57 ET | 490 | 0.4874 |
| 09:59 ET | 300 | 0.4802 |
| 10:01 ET | 499 | 0.4838 |
| 10:03 ET | 200 | 0.4875 |
| 10:10 ET | 1800 | 0.48565 |
| 10:12 ET | 5000 | 0.4857 |
| 10:14 ET | 2685 | 0.474 |
| 10:15 ET | 500 | 0.47655 |
| 10:19 ET | 107 | 0.48 |
| 10:21 ET | 207 | 0.47655 |
| 10:28 ET | 384 | 0.4731 |
| 10:30 ET | 110 | 0.478 |
| 10:37 ET | 4000 | 0.477999 |
| 10:48 ET | 2124 | 0.4721 |
| 10:51 ET | 100 | 0.4721 |
| 10:55 ET | 3433 | 0.478 |
| 11:04 ET | 2000 | 0.478 |
| 11:06 ET | 500 | 0.4779 |
| 11:08 ET | 400 | 0.478 |
| 11:15 ET | 200 | 0.4723 |
| 11:18 ET | 3131 | 0.478 |
| 11:20 ET | 4300 | 0.4756 |
| 11:24 ET | 1000 | 0.4779 |
| 11:36 ET | 900 | 0.4754 |
| 11:38 ET | 1079 | 0.4754 |
| 12:03 ET | 6956 | 0.48 |
| 12:07 ET | 100 | 0.4818 |
| 12:09 ET | 1500 | 0.487999 |
| 12:18 ET | 700 | 0.4818 |
| 12:20 ET | 6500 | 0.4881 |
| 12:36 ET | 100 | 0.4836 |
| 12:39 ET | 100 | 0.4859 |
| 12:56 ET | 2930 | 0.4847 |
| 01:06 ET | 1000 | 0.4813 |
| 01:08 ET | 7550 | 0.481401 |
| 01:26 ET | 300 | 0.486 |
| 01:30 ET | 4000 | 0.4847 |
| 01:32 ET | 2000 | 0.4815 |
| 01:33 ET | 10000 | 0.481533 |
| 01:35 ET | 10200 | 0.4815 |
| 01:37 ET | 20100 | 0.481 |
| 01:39 ET | 2838 | 0.48295 |
| 01:42 ET | 4141 | 0.481 |
| 01:44 ET | 3418 | 0.481 |
| 01:46 ET | 1904 | 0.48 |
| 01:55 ET | 17985 | 0.4756 |
| 02:00 ET | 100 | 0.481435 |
| 02:20 ET | 500 | 0.4783 |
| 02:26 ET | 500 | 0.4777 |
| 02:29 ET | 1100 | 0.4776 |
| 02:31 ET | 1600 | 0.4774 |
| 02:40 ET | 100 | 0.4719 |
| 02:42 ET | 1000 | 0.477399 |
| 02:56 ET | 1080 | 0.4772 |
| 03:05 ET | 100 | 0.4759 |
| 03:16 ET | 57541 | 0.46 |
| 03:18 ET | 37056 | 0.4563 |
| 03:20 ET | 2400 | 0.458 |
| 03:23 ET | 2600 | 0.4591 |
| 03:25 ET | 3400 | 0.461201 |
| 03:27 ET | 3250 | 0.462 |
| 03:32 ET | 10168 | 0.4589 |
| 03:36 ET | 4654 | 0.4619 |
| 03:48 ET | 100 | 0.4619 |
| 03:56 ET | 263 | 0.462 |
| 03:59 ET | 4445 | 0.462 |
Yesterday
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide, from 7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
Sep 17, 2024
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection, from 1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 40.6M | -0.6x | --- |
LAVA Therapeutics NV | 43.4M | -1.8x | --- |
Dyadic International Inc | 34.2M | -4.2x | --- |
Marker Therapeutics Inc | 31.4M | -2.8x | --- |
Omega Therapeutics Inc | 49.9M | -0.7x | --- |
OncoCyte Corp | 41.6M | -0.7x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $40.6M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 3.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
